Palbociclib

證據等級: L5

預測適應症: 10 個

Note before the report: predicted_indications[0] (hyperthyroidism, score 99.44%) is explicitly flagged in its own repurposing_rationale as having “no mechanistic link… likely knowledge-graph noise,” with zero supporting trials or literature. Mechanically using it as the headline candidate would misrepresent the evidence. I used rheumatoid arthritis (rank 3, the only candidate with an actual evidentiary trail — L4/S1/”Research Question”) as the report’s headline indication instead, and added a section covering the other four candidates so nothing in the pack is hidden — most importantly the thrombotic-disease entries, which the pack itself flags as an adverse-event signal, not a treatment opportunity.

Palbociclib: From Breast Cancer to Rheumatoid Arthritis

One-Sentence Summary

Palbociclib is a CDK4/6 inhibitor used in HR-positive/HER2-negative advanced breast cancer (per the supporting literature in this pack; the drug is not currently marketed in Denmark). Among five candidate indications flagged by TxGNN, Rheumatoid Arthritis carries the most credible — though still early — signal, supported by 1 case report and 3 preclinical/cohort studies. The single highest-scoring candidate (hyperthyroidism) has no supporting trials or literature and is assessed by the underlying evidence pack itself as likely graph noise.

Quick Overview

Item	Content
Original Indication	Not confirmed by Danish marketing-authorisation data (drug not marketed); literature in this pack consistently describes use in advanced HR+/HER2- breast cancer
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.36%
Evidence Level	L4
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this drug in the evidence pack (flagged as a High-severity data gap). Based on known information, palbociclib is a CDK4/6 inhibitor that blocks G1→S cell-cycle progression; this mechanism is well established in its use for advanced HR+/HER2- breast cancer, as reflected in several of the safety-literature citations in this pack (e.g. PMID 35300061, PMID 40504547).

The rheumatoid arthritis link is mechanistically distinct from tumour growth inhibition: synovial hyperplasia in RA has been shown to be partly CDK6-dependent in animal models (PMID 39940918), and cell-cycle inhibition of synovial fibroblasts with CDK inhibitors ameliorated arthritis in preclinical models without suppressing acquired immunity (PMID 25165034). A single case report describes apparent amelioration of pre-existing RA in a breast-cancer patient started on palbociclib (PMID 33587021), and a 2025 cohort study looked at immune-mediated disease prevalence in CDK4/6i-treated patients (PMID 40504547).

This is a plausible but early-stage mechanistic hypothesis — it rests on one human case report and animal/preclinical data, not on any controlled human trial. It should be treated as a research question, not a therapeutic claim.

Clinical Trial Evidence

Currently no related clinical trials registered for rheumatoid arthritis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40504547	2025	Cohort	The Oncologist	Investigated prevalence of autoimmune disease in HR+/HER2- breast cancer patients on CDK4/6 inhibitors + endocrine therapy, seeking predictive biomarkers
39940918	2025	Preclinical/Animal Study	International Journal of Molecular Sciences	CDK6-dependent (CDK4-independent) synovial hyperplasia in arthritic mice; palbociclib explored as an RA treatment option
33587021	2021	Case Report	Modern Rheumatology Case Reports	Amelioration of rheumatoid arthritis observed in a breast-cancer patient treated with palbociclib
25165034	2016	Preclinical/Animal Study	Annals of the Rheumatic Diseases	CDK inhibition of synovial fibroblasts ameliorated arthritis in animal models without attenuating acquired immunity

Denmark Market Information

No marketing authorisations are currently on file for palbociclib in Denmark (market status: not marketed; 0 registered licences).

Cytotoxicity

Palbociclib’s original indication is oncological (advanced breast cancer per the supporting literature), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (CDK4/6 inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	High — literature in this pack (PMID 37994878) identifies bone marrow suppression as a common adverse event across CDK4/6 inhibitors
Emetogenicity Classification	Low
Monitoring Items	Complete blood count with differential (neutrophil count in particular); given the thrombotic-disease signal noted below, also monitor for signs/symptoms of thromboembolism
Handling Protection	Oral hazardous/antineoplastic agent — handle per institutional cytotoxic/hazardous drug handling protocols despite oral (non-parenteral) administration

Safety Considerations

No structured safety data (key warnings, contraindications, DDI) is available in this evidence pack — please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Important pharmacovigilance signal (from literature evidence, not the structured safety fields): Multiple FAERS disproportionality analyses and real-world cohort studies in this pack (PMID 39123221, 39083396, 41496429, 36794339, 35300061) consistently associate CDK4/6 inhibitors, including palbociclib, with an increased risk of thromboembolic events. This is an adverse-event signal, not a therapeutic indication — see “Other Predicted Candidates” below.

Other Predicted Candidates (Not Prioritized)

This evidence pack contained five distinct TxGNN candidate indications for palbociclib. Only rheumatoid arthritis (above) had any supporting evidence. The others are documented here for transparency:

Disease	Score	Evidence Level	Why Deprioritized
Hyperthyroidism	99.44% (highest raw score)	L5	No mechanistic link identified; no literature or trials. The evidence pack’s own rationale text assesses this as likely knowledge-graph noise.
Thrombotic disease	99.32%	L4	⚠️ Direction-of-effect warning: pharmacovigilance literature shows CDK4/6 inhibitors increase thrombosis risk — this is a safety signal, not a treatment opportunity. The two associated trials (NCT05468697, NCT05371275) are unrelated combination/safety studies, not thrombotic-disease treatment trials, and one was withdrawn with 0 enrollment.
Resistance to thyroid hormone (THRB mutation)	99.30%	L5	Rare genetic nuclear-receptor disorder with no known biological link to CDK4/6 pathway; no literature or trials.
Brachydactyly-syndactyly syndrome	98.996%	L5	Rare skeletal developmental syndrome with no known link to CDK4/6 pathway; no literature or trials.

Conclusion and Next Steps

Decision: Hold

Rationale: The only candidate with any supporting evidence — rheumatoid arthritis — rests on a single case report and preclinical/animal mechanistic data, with no controlled human trials (decision stage S1, “Research Question”). This does not meet the bar for progressing toward clinical evaluation. The top-scoring TxGNN candidate (hyperthyroidism) has no supporting evidence at all, and the thrombotic-disease candidate is actually a safety signal working against, not for, repurposing.

To proceed, the following is needed:

Detailed mechanism of action (MOA) data (currently a High-severity data gap)
Official SmPC-derived warnings, contraindications, and drug interaction data (currently a Blocking data gap)
A prospective, controlled study design testing CDK4/6 inhibition specifically in RA, rather than relying on incidental case-report observation
Danish/EU regulatory consultation, since palbociclib holds no marketing authorisation in Denmark at present
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.